Graphene stocks
Zentek Ltd. (Nasdaq: ZTEK) announced on July 3, 2026, that it has received Health Canada approval for its graphene--based rapid diagnostic platform for the detection of multiple respiratory pathogens. The technology utilizes a graphene--functionalized biosensor to provide results in under five minutes with high sensitivity. This regulatory milestone allows the company to begin commercial sales to healthcare providers across Canada, with international filings currently underway. Market analysts suggest this approval significantly de--risks the company's medical technology portfolio and provides a clear path to near--term revenue generation.